Mereo BioPharma (MREO) Receivables - Net (2022 - 2023)

Mereo BioPharma (MREO) posted quarterly Receivables - Net of $9.9 million for Q2 2023, up 1005.09% quarter-over-quarter from $893771.4 in Q4 2022.

Mereo BioPharma (MREO) Receivables - Net (2022 - 2023) Analysis & Trends

Mereo BioPharma (MREO) has reported Receivables - Net for 2 consecutive years, with $9.9 million the latest figure, recorded in Q2 2023.

In Q2 2023, Receivables - Net changed N/A year-over-year to $9.9 million; the TTM figure through Jun 2023 stood at $9.9 million (changed N/A YoY), while the FY2022 annual figure was $893771.4, changed N/A from the prior year.
Receivables - Net grew to $9.9 million in Q2 2023 per MREO's latest filing, from $893771.4 in the prior quarter.
Across five years, Receivables - Net topped out at $9.9 million in Q2 2023 and bottomed at $893771.4 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.09 Bn	131.23 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.66 Bn	77.66 Bn	3.93 Bn
3	Argenx Se	64.86 Bn	59.67 Bn	1.37 Bn
4	Moderna	58.07 Bn	52.93 Bn	52.00 Mn
5	BeOne Medicines	41.87 Bn	36.77 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.45 Bn	28.15 Bn	992.69 Mn
7	BioNTech SE	27.90 Bn	9.51 Bn	668.28 Mn
8	Insmed	27.40 Bn	26.24 Bn	358.27 Mn
9	Royalty Pharma	27.28 Bn	26.45 Bn	-
10	Mereo BioPharma	47.59 Mn	47.59 Mn	-

Download Data